employer glp-1 coverage news Employers push health savings plans, nutritional counseling to avoid for weight loss Who Gets the Shot? GLP-1

Over time, obese patients lose roughly 12% of their body weight on Wegovy (semaglutide) and about 18% on Zepbound (tirzepatide, which targets GLP-1 and another gut hormone, GIP.) Diana Thiara, MD, medical director of the UCSF Weight Management Program, says the results can be amazing and life-changing for people with obesity, a condition linked to a host of health risks

Sigrid Breit, lead author, University of Bern, Switzerland Mental illnesses are associated with an increased risk of weight gain and metabolic disorders like obesity and type 2 diabetes

That means your first month might be on a lower dose, which can limit results early on

Instead, its activity is associated with adrenergic receptorlinked pathways in adipocytes